Ionic liquid based antibacterial-anti-inflammatory integrated bioactive nanoparticle with microwave sensitivity as well as preparation method and application of ionic liquid based antibacterial-anti-inflammatory integrated bioactive nanoparticle

Abstract

The invention relates to the technical field of abdominal wall adhesion materials induced by prevention and treatment of bacterial infection, and discloses an ionic liquid-based antibacterial-anti-inflammatory integrated bioactive nanoparticle with microwave sensitivity, a preparation method and application of the ionic liquid-based antibacterial-anti-inflammatory integrated bioactive nanoparticle. Then, the surfaces of the hollow nano particles are modified with bacteria specific targeting molecule 3-aminophenylboronic acid, and PBA-HPDA is formed; finally, chlorogenic acid and quaternary ammonium salt are combined according to a certain proportion to form ionic liquid (ILs) with a microwave heat effect, the ionic liquid (ILs) is wrapped in HPDA, and composite nanoparticles PBA-HPDA-CAQAC are formed. The nano particle material prepared by the invention has microwave heat effect and antibacterial and anti-inflammatory integrated biological activity, and has excellent bactericidal and anti-inflammatory effects.

Description

Technical Field

[0001] The invention relates to the technical field of materials for preventing and treating abdominal wall adhesion induced by bacterial infection, and in particular to a microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated biologically active nanoparticle, a preparation method and an application thereof. Background Art

[0002] Abdominal wall adhesions induced by bacterial infection are abnormal adhesions between the parietal peritoneum and the visceral peritoneum, which can cause great harm to patients, such as persistent chronic pain or discomfort caused by adhesion and traction, functional disorders caused by displacement or compression of organs, and complications such as adhesive intestinal obstruction. Therefore, the prevention and treatment of abdominal wall adhesions are of great significance for patients to maintain their health and improve their quality of life.

[0003] After the patient's abdominal wall is injured, bacterial infection can cause local inflammatory reactions and lead to the release of chemokines, which further leads to the accumulation of fibrin bundles and abdominal wall adhesions. Taking active preventive measures based on the causes and pathogenesis of adhesion formation can reduce the occurrence of adhesions. At present, in addition to the meticulous and standardized surgical operations in the early stage, the use of materials and drugs to prevent adhesions can also help patients' wound healing after surgery. Commonly used drugs in clinical practice are generally antibiotics and non-steroidal anti-inflammatory drugs, but the body's resistance and dependence limit the application of such drugs.

[0004] Therefore, a synergistic integrated bactericidal and anti-inflammatory method of nanoparticle materials with integrated biological activity of microwave thermal effect, antibacterial and anti-inflammatory can effectively avoid the impact of bacterial infection on the body and reduce the occurrence of severe inflammatory response, which will have far-reaching significance for the promotion and application of drugs for the prevention and treatment of abdominal wall adhesions. Summary of the invention

[0005] Purpose of the invention: In view of the problems existing in the prior art, the present invention provides a microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated biological activity nanoparticles, preparation methods and applications. The nanoparticles use hollow polymerized dopamine (HPDA) as a carrier, modify the bacteria-specific targeting molecule 3-aminophenylboronic acid (PBA) on the HPDA surface, and encapsulate chlorogenic acid (CA) and quaternary ammonium salt (QAC) inside the HPDA to form an ionic liquid (ILs) with microwave thermal effect. The nanoparticle material provided by the present invention has microwave thermal effect, antibacterial and anti-inflammatory integrated biological activities, and has excellent bactericidal and anti-inflammatory effects.

[0006] Technical solution: In the first aspect, the present invention provides an ionic liquid-based antibacterial and anti-inflammatory integrated biologically active nanoparticle with microwave sensitivity, wherein the nanoparticle uses hollow polymerized dopamine as a carrier, the surface of the hollow polymerized dopamine is modified with the bacteria-specific targeting molecule 3-aminophenylboronic acid, and the interior of the hollow polymerized dopamine is wrapped with an ionic liquid with microwave thermal effect formed by the combination of chlorogenic acid and quaternary ammonium salt.

[0007] In a second aspect, the present invention provides a method for preparing the microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated biologically active nanoparticles as described above, comprising the following steps: S1. dispersing the hollow polymerized dopamine nanoparticles in a buffer solution containing 3-aminophenylboronic acid and stirring to obtain PBA-modified nanoparticles; S2. Mixing a quaternary ammonium salt, chlorogenic acid and methanol, stirring under anaerobic conditions until viscous, to obtain an ionic liquid; preferably, the present invention utilizes the interaction between the positive charge in the quaternary ammonium salt and the negative charge in the chlorogenic acid to synthesize the ionic liquid; S3. The PBA-modified nanoparticles obtained in S1 are placed in methanol, ultrasonically dispersed, and then the ionic liquid obtained in S2 is added, stirred under vacuum suction until the solvent is discharged, and washed to obtain microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated biologically active nanoparticles.

[0008] Furthermore, in S1, the buffer is one of a tris(hydroxymethylaminomethane) buffer or a phosphate buffer, and the pH value is preferably 8.5.

[0009] Further, in S1, the concentration of the 3-aminophenylboronic acid in the buffer solution is 1 mg / mL; In S1, the mass ratio of the hollow polymerized dopamine nanoparticles to the 3-aminophenylboronic acid is 1:1.

[0010] Furthermore, in S1, the specific condition of the stirring is stirring at a constant temperature for 24 to 48 hours.

[0011] Preferably, after the stirring reaction in S1 is completed, washing and drying are sequentially performed to obtain PBA-modified nanoparticles; wherein the washing is preferably performed by flowing rinsing with deionized water; and the drying is preferably performed by vacuum drying at 60° C. for 12 to 24 h.

[0012] Furthermore, in S2, the mass ratio of the quaternary ammonium salt to the chlorogenic acid is 1-3:1.

[0013] Furthermore, in S2, the specific conditions for stirring are stirring at 30-50° C. for 4-48 h; preferably stirring in a constant temperature water bath.

[0014] Preferably, the oxygen-free condition preferably uses nitrogen as the protective gas.

[0015] Preferably, after the S2 reaction is completed, it also includes drying to obtain the ionic liquid; wherein the drying is preferably vacuum drying at 37° C. for 12 to 24 h.

[0016] Furthermore, in S3, the mass ratio of the PBA-modified nanoparticles to the ionic liquid is 1:10.

[0017] Preferably, in S3, the washing is washing with methanol and water multiple times.

[0018] In a third aspect, the present invention also provides an application of the microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated bioactive nanoparticles as described above in the technical field of materials for preventing and treating abdominal wall adhesions induced by bacterial infections.

[0019] Beneficial effects: Compared with the prior art, the microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated biologically active nanoparticle material provided by the present invention can not only indirectly reduce the occurrence of local inflammatory reactions through bactericidal effects, but also directly exert anti-inflammatory effects, reduce the damage of inflammatory reactions, and avoid the problems of antibiotic resistance and dependence in traditional strategies. The specific beneficial effects are as follows: (1) In the present invention, HPDA nanoparticles present a hollow internal structure, which provides sufficient space for the loading of drug molecules, and PBA, as an organic compound, has the function of targeting bacteria; CA, which constitutes the ionic liquid, can effectively remove free radicals in the body and stimulate immune cells to transform into anti-inflammatory cells, thereby producing an anti-inflammatory effect; QAC, another component of the ionic liquid, contains NH4 + Can be used with the COO in CA - ILs are formed through electrostatic forces and hydrogen bonds and other interaction forces. The formed ILs have good microwave thermal effect, and the NH4+ in the ILs can interact with negatively charged bacteria to achieve a certain bactericidal effect; the ILs finally constructed can achieve the synergy of microwave heat and chemical sterilization under microwave stimulation, and the CA of ILs can maintain excellent anti-inflammatory effect.

[0020] (2) In the present invention, the selected quaternary ammonium salts and ionic liquids under microwave thermal effect conditions achieve multiple bactericidal effects without producing drug resistance. At the same time, the disadvantage of poor cell compatibility caused by direct use of quaternary ammonium salts is also effectively avoided. Since quaternary ammonium salts have strong toxicity, the combination of chlorogenic acid and quaternary ammonium salts reduces the content of quaternary ammonium salts in the drug, effectively reducing cytotoxicity. In addition, chlorogenic acid also acts as an anti-inflammatory substance, directly reducing the inflammatory response, further enhancing the biocompatibility and antibacterial properties of the nanoparticles, and achieving mild, non-irritating bactericidal and anti-inflammatory effects.

[0021] (3) The preparation method of the nanoparticle material (PBA-HPDA@CAQAC) with integrated microwave thermal effect, antibacterial and anti-inflammatory properties provided by the present invention is simple to operate and easy to realize industrial production. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 A schematic diagram of the structure of the microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated bioactive nanoparticles (PBA-HPDA@CAQAC) prepared by the present invention; Figure 2 TEM image of the microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated bioactive nanoparticles (PBA-HPDA@CAQAC) of the present invention; Figure 3 (a) HPDA C1s spectrum, (b) PBA-HPDA C1s spectrum, (c) PBA-HPDA@CAQAC C1s spectrum; Figure 4 The full XPS spectra of PDA, HPDA, and PBA-HPDA; Figure 5 (a) CAQAC standard curve, (b) CAQAC release curve; Figure 6 (a) Microwave thermal effect diagram of different samples at 2 mg / mL, (b) Microwave thermal effect diagram of HPDA@ILs at different concentrations; Figure 7 (a) Photo of solid culture medium of Staphylococcus aureus, (b) survival rate of Staphylococcus aureus; Figure 8 It is the in vitro ROS clearance curve; Fig. 9 (a) In vitro blood compatibility graph, (b) In vitro L929 cell CCK-8 statistical graph, (c) In vitro RAW 264.7 cell CCK-8 statistical graph; Fig.10 It is a representative scatter plot of M1 and M2 phenotypes of each sample by flow cytometry of the present invention. DETAILED DESCRIPTION

[0022] The present invention is described in detail below in conjunction with the embodiments.

[0023] It should be noted that, in the present invention, unless otherwise specified, the raw materials used are all commercially available products in the art.

[0024] The present invention has no particular limitation on the specific manner of the application, and any manner familiar to those skilled in the art may be used.

[0025] Implementation 1: This embodiment provides an ionic liquid-based antibacterial and anti-inflammatory integrated bioactive nanoparticle (PBA-HPDA@CAQAC) with microwave sensitivity. The nanoparticle uses hollow polymerized dopamine (HPDA) as a carrier, and then the bacteria-specific targeting molecule 3-aminophenylboronic acid (PBA) is modified on the surface of the hollow nanoparticle; finally, chlorogenic acid (CA) and quaternary ammonium salt (QAC) are combined in a certain proportion to form an ionic liquid (ILs) with microwave thermal effect, and the ILs are encapsulated inside the HPDA.

[0026] This embodiment also provides a method for preparing the above-mentioned nanoparticles, which is as follows: 1) Disperse 50 mg of hollow polymeric dopamine nanoparticles (HPDA NPs) in 50 mL of Tris buffer (pH=8.5) containing 50 mg of 3-aminophenylboronic acid (PBA) and stir for 24 h to obtain PBA-modified nanoparticles, which are denoted as PBA-HPDA.

[0027] 2) Synthesize ionic liquids through the interaction of positive charges in quaternary ammonium salt (QAC) and negative charges in chlorogenic acid (CA). Specifically, QAC (0.5 g) and CA (0.5 g) were added to a round-bottom flask containing methanol (20 mL) and filled with nitrogen to remove air, and then stirred in a constant temperature water bath at 37°C for 24 h. Subsequently, the mixture was kept under vacuum at 37 degrees until it became viscous to obtain an ionic liquid, which was recorded as CAQAC.

[0028] 3) PBA-HPDA (100 mg) obtained in step 1) was dispersed in methanol (20 mL) and ultrasonically dispersed for 5 min. Then it was poured into a round-bottom culture bottle containing CAQAC (1 g). Subsequently, the mixed solution was stirred under vacuum suction until the solvent was discharged. After washing with methanol and water once each, PBA-HPDA-coated CAQAC NPs were obtained, i.e., microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated bioactive nanoparticles, denoted as PBA-HPDA@CAQAC.

[0029] Implementation 2: This embodiment provides a method for preparing microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated bioactive nanoparticles (PBA-HPDA@CAQAC), as follows: 1) Disperse 75 mg of hollow polymeric dopamine nanoparticles (HPDA NPs) in 75 mL of Tris buffer (pH=8.5) containing 75 mg of 3-aminophenylboronic acid (PBA) and stir for 48 h to obtain PBA-modified nanoparticles, which are denoted as PBA-HPDA.

[0030] 2) Synthesize ionic liquids through the interaction of positive charges in quaternary ammonium salt (QAC) and negative charges in chlorogenic acid (CA). Specifically, QAC (1 g) and CA (0.5 g) were added to a round-bottom flask containing methanol (30 mL) and filled with nitrogen to remove air, and then stirred in a 37°C constant temperature water bath for 48 h. Subsequently, the mixture was kept under vacuum at 37 degrees until it became viscous to obtain an ionic liquid, which was recorded as CAQAC.

[0031] 3) PBA-HPDA (150 mg) obtained in step 1) was dispersed in methanol (20 mL) and ultrasonically dispersed for 5 min. Then it was poured into a round-bottom culture bottle containing CAQAC (1.5 g). Subsequently, the mixed solution was stirred under vacuum suction until the solvent was discharged. After washing with methanol and water once each, PBA-HPDA-coated CAQAC NPs were obtained, i.e., microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated bioactive nanoparticles, denoted as PBA-HPDA@CAQAC.

[0032] Implementation 3: This embodiment provides a method for preparing microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated bioactive nanoparticles (PBA-HPDA@CAQAC), as follows: 1) Disperse 100 mg of hollow polymeric dopamine nanoparticles (HPDA NPs) in 100 mL of Tris buffer (pH=8.5) containing 100 mg of 3-aminophenylboronic acid (PBA) and stir for 48 h to obtain PBA-modified nanoparticles, which are denoted as PBA-HPDA.

[0033] 2) Synthesize ionic liquids through the interaction of positive charges in quaternary ammonium salt (QAC) and negative charges in chlorogenic acid (CA). Specifically, QAC (1.5 g) and CA (0.5 g) were added to a round-bottom flask containing methanol (30 mL) and filled with nitrogen to remove air, and then stirred in a constant temperature water bath at 37°C for 48 h. Subsequently, the mixture was kept under vacuum at 37 degrees until it became viscous to obtain an ionic liquid, which was recorded as CAQAC.

[0034] 3) PBA-HPDA (200 mg) obtained in step 1) was dispersed in methanol (20 mL) and ultrasonically dispersed for 5 min. Then it was poured into a round-bottom culture bottle containing CAQAC (2 g). Subsequently, the mixed solution was stirred under vacuum suction until the solvent was discharged. After washing with methanol and water once each, PBA-HPDA-coated CAQAC NPs were obtained, i.e., microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated bioactive nanoparticles, denoted as PBA-HPDA@CAQAC.

[0035] The microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated bioactive nanoparticles (PBA-HPDA@CAQAC) prepared by the present invention were characterized: Figure 3 In the figure, (a) is the C1s spectrum of HPDA, (b) is the C1s spectrum of PBA-HPDA, and (c) is the C1s spectrum of PBA-HPDA@CAQAC prepared in Embodiment 1. Compared with (a) HPDA, (b) PBA-HPDA has the C=N characteristic peak introduced by PBA, indicating that PBA is successfully connected to the surface of HPDA. Compared with (b) PBA-HPDA, (c) PBA-HPDA@CAQAC has no new characteristic peak, indicating that the loading of CAQAC has no effect on the PBA connected to the surface.

[0036] Figure 4 This is the full XPS spectrum.

[0037] The performance test of the microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated biologically active nanoparticles (PBA-HPDA@CAQAC) prepared by the present invention was carried out (all PBA-HPDA@CAQAC prepared in Implementation Example 1 was used as a sample): (1) Test on release behavior: In order to study the release behavior of PBA-HPDA@CAQAC samples, the release behavior was studied. Since PBA affects the detection of drug release, HPDA@CAQAC was selected for drug release research. For CAQAC release determination, UV-visible spectroscopy was used to establish a standard curve. HPDA@CAQAC nanoparticles (1 mg) were dispersed in 4 mL PBS (pH=7.4) at 37 °C and shaken at 120 rpm to simulate the release of the drug in vivo. After centrifuging the mixed solution for UV-visible spectrophotometer analysis at regular intervals, 4 ml of supernatant was aspirated and 4 ml of fresh buffer solution was added to continue the release of CAQAC. The amount of CAQAC released from the nanoparticles was determined by its absorbance at 324 nm and recorded to draw the release curve.

[0038] like Figure 5 The standard curve of CAQAC release is shown in (a). 2 The value of reaches 0.999, indicating that the release data has a good fit; Figure 6 The curve of CAQAC release shown in (b) shows that PBA-HPDA@CAQAC rapidly releases CAQAC within 1 h, and the release behavior is completed at 3 h, with a drug release rate of 28%.

[0039] (2) In vitro microwave thermal effect: The microwave thermal effect of the nanoparticles in vitro was evaluated by microwave heating experiments. Briefly, different amounts of PBA-HPDA@CAQAC (0, 0.5, 1, 1.5, 2, and 2.5 mg) were dispersed in saline (1 mL) and placed in a microwave therapy probe for 10 min. A thermal imager was used to observe the microwave thermal effect of samples with different concentrations under microwave (0.5 W / cm2) irradiation.

[0040] like Figure 6 The microwave thermal effect diagram of different samples at 2 mg / mL shown in (a) shows that the ionic liquid CAQAC has a strong microwave effect. At the same sample concentration, the nanoparticles containing CAQAC heat up faster and at a higher temperature after microwave irradiation. Figure 6 (b) shows the microwave thermal effect diagram of PBA-HPDA@CAQAC with different concentrations. It shows that the higher the concentration of ionic liquid CAQAC, the better its microwave effect. After microwave irradiation, the higher the concentration of CAQAC, the faster it heats up and the higher the temperature.

[0041] (3) In vitro antibacterial function test: Gram-positive Staphylococcus aureus was selected as a bacterial model to evaluate the antibacterial activity of nanoparticles. The bacterial suspension in the exponential growth phase was diluted to 1×106 CFU / mL, and then 100μL of the bacterial suspension was incubated with nanoparticles and sterile PBS at 37°C for 4 h (the microwave group was irradiated for 30 minutes before incubation). Finally, the bacterial suspension was diluted with 3ml of sterile PBS, and the resulting bacterial solution (100μL) was evenly inoculated on an agar plate and cultured at 37°C for 16h. The number of colonies was counted and counted for analysis.

[0042] like Figure 7 (a) shows a solid culture medium of Staphylococcus aureus. Figure 7 (b) shows the survival rate of Staphylococcus aureus. Under non-microwave irradiation, a large number of bacteria were present on the surface of the Control, HPDA, and PBA-HPDA samples, and the PBA-HPDA@CAQAC sample had a slight bactericidal effect, indicating that CAQAC has certain bactericidal properties; under microwave irradiation, compared with the Control, HPDA, and PBA-HPDA sample groups, the PBA-HPDA@CAQAC sample had basically no colonies on the surface of the culture medium, and the bactericidal rate could reach 100%, indicating that microwave heat and CAQAC achieved a physical and chemical synergistic and efficient integrated bactericidal effect.

[0043] (4) DPPH in vitro ROS scavenging function test: The antioxidant activity of the nanoparticles was evaluated by scavenging 1,1-diphenyl-2-trinitrophenylhydrazine (DPPH) free radicals. Briefly, various nanoparticle samples were mixed in 3 mL of DPPH ethanol solution (40 μg / mL) and reacted with each other in the dark. UV-visible spectroscopy was used to record the complete wavenumber scan curve at regular intervals. Where Acontrol is the absorbance of the blank containing only DPPH, and Asample is the maximum absorbance of the mixture with DPPH and various samples. Figure 8 The in vitro ROS scavenging curve is shown. As time goes by, the absorbance of the HPDA and PBA-HPDA sample solutions decreases, and the absorbance of the BA-HPDA@CAQAC sample solution decreases significantly, indicating that the PBA-HPDA@CAQAC sample has good DPPH free radical scavenging ability and excellent antioxidant capacity.

[0044] (5) In vitro hemolysis and cytotoxicity test: The cytocompatibility of the nanoparticles was evaluated by in vitro hemolysis test. Red blood cells (RBCs) were separated from serum by centrifugation (1000 rpm, 15 min), then washed three times with saline and diluted 20 times to obtain RBCs suspension. As controls, RBCs were treated with saline (negative control) and ultrapure water (positive control). Then, equal amounts of RBCs suspension were mixed with different samples, incubated at 37°C for 1 h, and plasma was separated by centrifugation (3000 rpm, 3 min). Then, the upper ultrafiltrate was transferred to a 96-well plate, and the absorbance of each ultrafiltrate at 540 nm was measured using a microplate reader. Fig. 9 In vitro blood compatibility diagram shown in (a). Except for the positive control, all samples showed no significant difference compared with the negative control, indicating that the samples had good blood compatibility and red blood cells could survive normally on their surface.

[0045] The cytotoxicity of nanoparticles was tested using a cell proliferation activity kit (CCK-8 method). L929 fibroblasts were seeded in a 96-well microplate, with 1×104 cells per well, and cultured for 24 hours. After the cells adhered, different samples were added to each well and incubated with the cells for different time intervals. Then 200 μL of CCK-8 solution (culture volume was 10 v / v%) was added to the well and incubated for 1 h. The absorbance of the cells in each well (experimental group and blank group) was detected using a multifunctional microplate reader at 450 nm. Fig. 9 (b) shows the CCK-8 statistical diagram of L929 cells in vitro. Fig. 9 (c) shows the CCK-8 statistical graph of RAW 264.7 cells in vitro. Compared with the Control, the cell survival rates of all samples were above 95%, and the cell survival rates were close to 100%, indicating that the samples of the present invention have good cell compatibility and low cytotoxicity.

[0046] (6) Flow cytometry: Flow cytometry was used to detect the anti-inflammatory activity of nanoparticles. RAW264.7 cells were seeded in a 24-well microplate, and 1×105 cells were incubated in each well for 24 h. Then, macrophages were stimulated with LPS (500 ng / mL) for 12 h, and extracts of different samples were added to each well for incubation for 24 h. The extracts were stained with FITC-CD80 and FITC-CD206 antibodies at 4°C for 30 min, and analyzed by flow cytometry. Fig.10The representative scatter plots of flow cytometry M1 and M2 phenotypes are shown. Compared with Control, the number of M2 cells in the PBA-HPDA@CAQAC sample increased significantly, and compared with Positive, the number of M2 cells in the PBA-HPDA@CAQAC sample decreased significantly, indicating that the loading of CAQAC greatly improved the anti-inflammatory ability of the sample, promoted the polarization of RAW 264,7 cells to M2 phenotype, inhibited the polarization of RAW 264,7 cells to M1 phenotype, and had a superior anti-inflammatory effect.

[0047] In summary, in the microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated bioactive nanoparticles (PBA-HPDA@CAQAC) prepared by the present invention, the hollow internal structure of HPDA nanoparticles provides sufficient space for the loading of drug molecules, and PBA, as an organic compound, has the function of targeting bacteria; CA, which constitutes the ionic liquid, can produce anti-inflammatory effects by scavenging free radicals and interacting with immune cells; QAC, another component of the ionic liquid, can combine with CA to form ILs, and the formed ILs and the NH4 + The synergy of microwave heat and chemical sterilization under microwave stimulation can be achieved, and at the same time, the CA of ILs can maintain excellent anti-inflammatory effects.

[0048] The above embodiments are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with the technology to understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent transformation or modification made according to the spirit of the present invention should be included in the protection scope of the present invention.

Claims

1. A microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated biologically active nanoparticle, characterized in that: The nanoparticles use hollow polymerized dopamine as a carrier, the surface of the hollow polymerized dopamine is modified with a bacteria-specific targeting molecule 3-aminophenylboronic acid, and the interior of the hollow polymerized dopamine is wrapped with an ionic liquid with a microwave thermal effect formed by combining chlorogenic acid and a quaternary ammonium salt.

2. A method for preparing microwave-sensitive ionic liquid-based antibacterial and anti-inflammatory integrated biologically active nanoparticles as claimed in claim 1, characterized in that: The following steps are involved: S1. Dispersing the hollow polymerized dopamine nanoparticles in a buffer solution containing 3-aminophenylboronic acid and stirring to obtain PBA-modified nanoparticles; S2. Mixing the quaternary ammonium salt, chlorogenic acid and methanol, and stirring under anaerobic conditions until it becomes viscous to obtain an ionic liquid; S3. The PBA-modified nanoparticles obtained in S1 are placed in methanol, ultrasonically dispersed, and then the ionic liquid obtained in S2 is added, stirred under vacuum suction until the solvent is discharged, and washed to obtain microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated biologically active nanoparticles.

3. The method for preparing microwave-sensitive ionic liquid-based antibacterial and anti-inflammatory integrated biologically active nanoparticles according to claim 2, characterized in that: In S1, the buffer is one of a tris buffer and a phosphate buffer.

4. The method for preparing microwave-sensitive ionic liquid-based antibacterial and anti-inflammatory integrated biologically active nanoparticles according to claim 2, characterized in that: In S1, the concentration of 3-aminophenylboronic acid in the buffer solution is 1 mg / mL; In S1, the mass ratio of the hollow polymerized dopamine nanoparticles to the 3-aminophenylboronic acid is 1:

1.

5. The method for preparing microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated biologically active nanoparticles according to claim 2, characterized in that: In S1, the specific conditions of the stirring are stirring at a constant temperature for 24 to 48 hours.

6. The method for preparing microwave-sensitive ionic liquid-based antibacterial and anti-inflammatory integrated biologically active nanoparticles according to claim 2, characterized in that: In S2, the mass ratio of the quaternary ammonium salt to the chlorogenic acid is 1-3:

1.

7. The method for preparing microwave-sensitive ionic liquid-based antibacterial and anti-inflammatory integrated biologically active nanoparticles according to claim 2, characterized in that: In S2, the specific conditions of the stirring are stirring at 30-50° C. for 4-48 h.

8. The method for preparing microwave-sensitive ionic liquid-based antibacterial and anti-inflammatory integrated biologically active nanoparticles according to claim 2, characterized in that: In S3, the mass ratio of the PBA-modified nanoparticles to the ionic liquid is 1:

10.

9. The method for preparing microwave-sensitive ionic liquid-based antibacterial and anti-inflammatory integrated biologically active nanoparticles according to claim 2, characterized in that: In S3, the washing specifically includes washing with methanol and water for multiple times.

10. Use of the microwave-sensitive ionic liquid-based antibacterial-anti-inflammatory integrated bioactive nanoparticles as claimed in claim 1 in the prevention and treatment of abdominal wall adhesions.

Images